Features and approaches to treating patients with concurrent lung cancer and lymphoproliferative disorders

Background. Epidemiological studies show that the incidence of synchronous multiple primary malignant neoplasms ranges from 2 % to 17 %. the co-occurrence of lung cancer and lymphoma accounts for 15 % of all combinations of lymphoproliferative diseases with malignant neoplasms of other organs. Currently, there is no universally accepted diagnostic and treatment strategy for this patient group. Objective: To present a series of clinical cases demonstrating the significance of a personalized approach in the diagnosis and treatment of patients with the concurrent diagnosis of lung cancer and lymphoproliferative diseases. Case reports. We report two cases of synchronous lung cancer and B-cell lymphoma. In both cases, diagnosis of multiple primary malignancies guided optimal treatment strategies. Conclusion. Lung cancer should be included in the differential diagnosis of pulmonary lesions in patients with chronic leukemia or lymphoma. a thorough examination and morphological verification of the identified changes in this group of patients will help to choose the correct treatment strategy.